8-KFiled Aug 9, 8:00 PM ET

Silence Therapeutics plc Reports Q2 2026 Financial Results

$SLN · Silence Therapeutics plc

Research Summary

AI-generated summary of this SEC filing

Updated

Silence Therapeutics plc Reports Q2 2026 Financial Results

What Happened
Silence Therapeutics plc announced its financial and business results for the quarter ended June 30, 2026 via a press release dated August 10, 2026. The company filed a Form 8-K on August 10, 2026 (Item 2.02) to furnish that press release with the SEC; the press release is included as Exhibit 99.1 to the filing.

Key Details

  • Press release and results announced on August 10, 2026.
  • Reporting period: quarter ended June 30, 2026.
  • Form 8-K Item 2.02: Results of Operations and Financial Condition (press release furnished).
  • Exhibit 99.1: Press Release (included with the 8-K).

Why It Matters
This filing makes Silence Therapeutics’ Q2 2026 quarterly results publicly available through the furnished press release. Retail investors should review the press release and the company’s subsequent SEC filings for specific financial metrics (revenue, expenses, cash position, and any management commentary or guidance) to assess the company’s recent operating performance and short-term outlook.